Corline Biomedical AB (CLBIO.ST)
SEK 8.98
(-1.34%)
SEK 8.98
(-1.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.78 Million SEK | -5.63% |
| 2022 | 7.19 Million SEK | -23.69% |
| 2021 | 9.42 Million SEK | 50.83% |
| 2020 | 6.25 Million SEK | 40.99% |
| 2019 | 4.43 Million SEK | -44.26% |
| 2018 | 7.95 Million SEK | 44.57% |
| 2017 | 5.5 Million SEK | 117.52% |
| 2016 | 2.52 Million SEK | -32.46% |
| 2015 | 3.74 Million SEK | -66.83% |
| 2014 | 11.28 Million SEK | 95.96% |
| 2013 | 5.76 Million SEK | -48.05% |
| 2012 | 11.08 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 13.57 Million SEK | 42.29% |
| 2024 Q1 | 9.54 Million SEK | 40.54% |
| 2023 Q1 | 7.83 Million SEK | 8.87% |
| 2023 Q3 | 5.43 Million SEK | -33.14% |
| 2023 Q4 | 6.78 Million SEK | 24.87% |
| 2023 FY | 6.78 Million SEK | -5.63% |
| 2023 Q2 | 8.13 Million SEK | 3.83% |
| 2022 Q1 | 5.91 Million SEK | -37.25% |
| 2022 Q4 | 7.19 Million SEK | -5.6% |
| 2022 Q3 | 7.62 Million SEK | 8.84% |
| 2022 FY | 7.19 Million SEK | -23.69% |
| 2022 Q2 | 7 Million SEK | 18.38% |
| 2021 FY | 9.42 Million SEK | 50.83% |
| 2021 Q3 | 3.76 Million SEK | -14.07% |
| 2021 Q4 | 9.42 Million SEK | 150.25% |
| 2021 Q1 | 4.77 Million SEK | -23.6% |
| 2021 Q2 | 4.38 Million SEK | -8.19% |
| 2020 Q1 | 5.27 Million SEK | 18.93% |
| 2020 FY | 6.25 Million SEK | 40.99% |
| 2020 Q3 | 4.99 Million SEK | -23.6% |
| 2020 Q4 | 6.25 Million SEK | 25.05% |
| 2020 Q2 | 6.54 Million SEK | 24.09% |
| 2019 Q2 | 6.28 Million SEK | 4.57% |
| 2019 FY | 4.43 Million SEK | -44.26% |
| 2019 Q4 | 4.43 Million SEK | -4.17% |
| 2019 Q3 | 4.62 Million SEK | -26.41% |
| 2019 Q1 | 6.01 Million SEK | -24.42% |
| 2018 Q2 | 3.86 Million SEK | 20.57% |
| 2018 Q3 | 8.6 Million SEK | 122.81% |
| 2018 Q4 | 7.95 Million SEK | -7.58% |
| 2018 FY | 7.95 Million SEK | 44.57% |
| 2018 Q1 | 3.2 Million SEK | -41.77% |
| 2017 Q3 | 7.58 Million SEK | -23.78% |
| 2017 Q2 | 9.95 Million SEK | -20.91% |
| 2017 Q1 | 12.59 Million SEK | 397.83% |
| 2017 Q4 | 5.5 Million SEK | -27.51% |
| 2017 FY | 5.5 Million SEK | 117.52% |
| 2016 FY | 2.52 Million SEK | -32.46% |
| 2016 Q4 | 2.52 Million SEK | -22.16% |
| 2016 Q3 | 3.24 Million SEK | -26.49% |
| 2016 Q2 | 4.42 Million SEK | 3.06% |
| 2016 Q1 | 4.28 Million SEK | 14.53% |
| 2015 Q4 | 3.74 Million SEK | 43.28% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q3 | 2.61 Million SEK | -8.18% |
| 2015 Q2 | 2.84 Million SEK | 0.0% |
| 2015 FY | 3.74 Million SEK | -66.83% |
| 2014 FY | 11.28 Million SEK | 95.96% |
| 2014 Q4 | 11.28 Million SEK | 0.0% |
| 2013 FY | 5.76 Million SEK | -48.05% |
| 2012 FY | 11.08 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| 2cureX AB (publ) | 2.93 Million SEK | -131.312% |
| Abliva AB (publ) | 16.78 Million SEK | 59.544% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 46.728% |
| AcouSort AB (publ) | 10.37 Million SEK | 34.583% |
| Active Biotech AB (publ) | 13.4 Million SEK | 49.336% |
| Alzinova AB (publ) | 9.33 Million SEK | 27.243% |
| Amniotics AB (publ) | 10.54 Million SEK | 35.631% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 14.593% |
| Aptahem AB (publ) | 8.99 Million SEK | 24.548% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -53.389% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 93.631% |
| BioInvent International AB (publ) | 90.45 Million SEK | 92.494% |
| BioArctic AB (publ) | 139.5 Million SEK | 95.133% |
| Biosergen AB | 5.08 Million SEK | -33.51% |
| Biovica International AB (publ) | 34.76 Million SEK | 80.473% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 57.877% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.566% |
| Camurus AB (publ) | 414.81 Million SEK | 98.363% |
| Cantargia AB (publ) | 54.97 Million SEK | 87.65% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -76.889% |
| CombiGene AB (publ) | 4.15 Million SEK | -63.354% |
| Cyxone AB (publ) | 4.69 Million SEK | -44.631% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 6.488% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 90.454% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 96.836% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 50.703% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 49.062% |
| Fluicell AB (publ) | 8.91 Million SEK | 23.847% |
| Genovis AB (publ.) | 98.04 Million SEK | 93.076% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 63.291% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.428% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 85.299% |
| Mendus AB (publ) | 51.22 Million SEK | 86.747% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 88.935% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 64.574% |
| I-Tech AB | 16.2 Million SEK | 58.106% |
| Intervacc AB (publ) | 21.68 Million SEK | 68.685% |
| Kancera AB (publ) | 17.97 Million SEK | 62.237% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 41.317% |
| LIDDS AB (publ) | 3.75 Million SEK | -80.751% |
| Lipum AB (publ) | 7.53 Million SEK | 9.936% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -31.621% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 94.524% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -187.791% |
| Nanologica AB (publ) | 79.32 Million SEK | 91.442% |
| NextCell Pharma AB | 13.68 Million SEK | 50.406% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 96.262% |
| OncoZenge AB (publ) | 1.69 Million SEK | -299.588% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -278.428% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 74.581% |
| Saniona AB (publ) | 86.08 Million SEK | 92.113% |
| Simris Alg AB (publ) | 148.93 Million SEK | 95.442% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 41.815% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 80.38% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -30.685% |
| SynAct Pharma AB | 51.83 Million SEK | 86.902% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 83.384% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.592% |
| Xintela AB (publ) | 14.01 Million SEK | 51.559% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 90.551% |
| Ziccum AB (publ) | 6.38 Million SEK | -6.277% |